HLA-A*0201 Positive Cells Present

9 clinical trials · Condition

Record	Firm	Date
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (NCT03450122)	M.D. Anderson Cancer Center	2018-09-13
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer (NCT03318900)	M.D. Anderson Cancer Center	2018-09-04
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NCT03506802)	Jonsson Comprehensive Cancer Center	2018-07-10
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia (NCT02770820)	Fred Hutchinson Cancer Center	2017-11-06
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NCT03240861)	Jonsson Comprehensive Cancer Center	2017-07-26
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma (NCT02408016)	Fred Hutchinson Cancer Center	2015-05-22
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT02396134)	City of Hope Medical Center	2015-05-21

Every clearance here is in the API, with alerts when new ones post.